Today: 1 May 2026
Lam Research stock slips 3% after fresh high as Citi, Deutsche Bank lift targets into earnings
23 January 2026
1 min read

Lam Research stock slips 3% after fresh high as Citi, Deutsche Bank lift targets into earnings

New York, Jan 22, 2026, 17:42 EST — After-hours

  • Lam Research shares dipped Thursday, retreating from the 52-week peak they hit just the day before
  • Ahead of Lam’s Jan. 28 quarterly earnings, Citi and Deutsche Bank both bumped up their price targets this week
  • Traders are focusing on chip-equipment spending forecasts for 2026, not just this quarter’s figures

Shares of Lam Research Corp fell 3.4% Thursday, closing at $220.70. During the day, the stock fluctuated between $238.20 and $219.39, and it held close to the closing price in after-hours trading.

The drop comes just a week ahead of Lam’s December-quarter earnings release on Jan. 28. Investors will focus on what management reveals about customer spending outlook for 2026, particularly around memory and advanced logic chips.

Citigroup boosted its price target for Lam to $265 from $190, maintaining a Buy rating. The firm described Lam as being in a “Phase 2 upcycle,” driven by wafer fab equipment spending edging closer to Citi’s bullish forecast. TipRanks

Deutsche Bank’s Melissa Weathers bumped her price target on Lam to $260 from $195, maintaining a Buy rating. She anticipates the company will deliver results “solidly above Street” expectations shortly. TipRanks

Lam took a notable hit on a day when U.S. stocks mostly rose—the S&P 500 gained 0.6%—yet the chip-equipment firm ended roughly 5% below its 52-week peak of $232.90, reached just Wednesday. Applied Materials slid around 2% during the session. Lam’s trading volume hovered near its recent average, according to MarketWatch data.

This group’s back-and-forth is nothing new. Targets jump up fast when analysts raise them, but then stocks swing wildly over minor details — order timing, who the customers are, or any sign that robust spending might be slowing down.

Lam supplies tools that deposit and etch thin layers on wafers. Demand usually tracks major capital spending at chipmakers, so the outlook commentary matters as much as the quarter’s revenue and profit.

The setup works two ways. A slip in customer capex or stricter export controls limiting shipments to China could disrupt forecasts — a risk peers have flagged as Washington ramps up restrictions.

Investors are keen on Lam’s take on backlog and shipments, plus how much of 2026 spending is just being pulled forward rather than actually growing. Margin discussions will be crucial, particularly if the more expensive tools and services are carrying a bigger load.

Lam’s earnings report and conference call are set for Jan. 28. Investors will zero in on the forward guidance, which will probably drive the initial market response more than the headline figures.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:14 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Microsoft stock drops after Redburn cuts target as Jan. 28 earnings loom
Previous Story

Microsoft stock drops after Redburn cuts target as Jan. 28 earnings loom

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings
Next Story

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Go toTop